251661-01-5

Basic information

• Product Name: Carbamic acid, (1-methylcyclopropyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (1-methylcyclopropyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl 1-MethylcyclopropylcarbaMate;N-Boc-1-MethylcyclopropanaMine;tert-Butyl (1-methylcyclopropyl)
• CAS NO: 251661-01-5
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.23678
• Product Categories: N-BOC
• Mol File: 251661-01-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 233.8±7.0 °C(Predicted)
• Appearance: /
• Density: 1.00±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.03±0.20(Predicted)
• CAS DataBase Reference: Carbamic acid, (1-methylcyclopropyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (1-methylcyclopropyl)-, 1,1-dimethylethyl ester (9CI)(251661-01-5)
• EPA Substance Registry System: Carbamic acid, (1-methylcyclopropyl)-, 1,1-dimethylethyl ester (9CI)(251661-01-5)

Safety Data

• Hazardous Substances Data: 251661-01-5(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (1-methylcyclopropyl)-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C9H17NO2. It is commonly known as tertiobutyl (1-methylcyclopropyl)carbamate. This chemical is used as an intermediate in the production of pesticides, herbicides, and other agricultural chemicals. It is also used as an intermediate in the synthesis of pharmaceutical compounds. However, it is important to handle this chemical with caution, as it can be harmful if it comes into contact with the skin or if it is ingested. Proper safety measures should be taken when working with this chemical in order to minimize the risk of exposure.

Upstream product

• 6914-76-7 1-Methyl-cyclopropanoic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 886583-34-2 3-bromo-N-[4-chloro-2-methyl-6-[[(1-methylcyclopropyl)amino]carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide 
• 88887-87-0 1-methylcyclopropylamine hydrochloride 

Relevant articles and documents

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.

A PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND

The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R1 and R2 are the same or different and each an optionally substituted aryl group etc, R0 is hydrogen atom, an alkyl group etc, E is a group of the formula: -C(=O)- or -SO?2#191-, R is a group of the following formula [i], [ii] or [iii] etc: Ring A is (a) a C?3-8#191 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R3 is an alkyl group optionally substituted by an alkylthio group, R4 is hydrogen atom, an alkyl group etc, one of RA and RB is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.

AMIDE DERIVATIVES

The invention concerns a compound of the Formula (I) wherein m is 0-2 and each R1 is a group such as hydroxy, halogeno, trifluoromethyl heterocyclyl and heterocyclyloxy; R2 is halogeno, trifluoromethyl or (1-6C)alkyl; R3 is hydrogen, halogeno or (1-6C)alkyl; and R4 is (3-6C)cycloalkyl;or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by cytokines.